.

BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
McKesson
UBS
Healthtrust
Cantor Fitzgerald
Fuji
Express Scripts
McKinsey
Fish and Richardson
Boehringer Ingelheim

Generated: November 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,555,581

« Back to Dashboard

Which drugs does patent 6,555,581 protect, and when does it expire?


Patent 6,555,581 protects LEVOXYL and is included in one NDA.

This patent has twenty-six patent family members in nine countries.

Summary for Patent: 6,555,581

Title: Levothyroxine compositions and methods
Abstract:The present invention generally relates to stable pharmaceutical compositions, and methods of making and administering such compositions. In one aspect, the invention features stabilized pharmaceutical compositions that include pharmaceutically active ingredients such as levothyroxine (T4) sodium and liothyronine (T3) sodium (thyroid hormone drugs), preferably in an immediate release solid dosage form. Also provided are methods for making and using such immediate release and stabilized compositions.
Inventor(s): Franz; G. Andrew (St. Louis, MO), Strauss; Elaine A. (Seminole, FL), DiMenna; Philip A. (St. Petersburg, FL), Gemma; Rocco L. (Dover, OH)
Assignee: Jones Pharma, Inc. (St. Petersburg, FL)
Application Number:10/077,677
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
King Pharms
LEVOXYL
levothyroxine sodium
TABLET;ORAL021301-001May 25, 2001AB1,AB3RXYesNo► Subscribe► Subscribe
King Pharms
LEVOXYL
levothyroxine sodium
TABLET;ORAL021301-002May 25, 2001AB1,AB3RXYesNo► Subscribe► Subscribe
King Pharms
LEVOXYL
levothyroxine sodium
TABLET;ORAL021301-003May 25, 2001AB1,AB3RXYesNo► Subscribe► Subscribe
King Pharms
LEVOXYL
levothyroxine sodium
TABLET;ORAL021301-004May 25, 2001AB1,AB3RXYesNo► Subscribe► Subscribe
King Pharms
LEVOXYL
levothyroxine sodium
TABLET;ORAL021301-005May 25, 2001AB1,AB3RXYesNo► Subscribe► Subscribe
King Pharms
LEVOXYL
levothyroxine sodium
TABLET;ORAL021301-006May 25, 2001AB1,AB3RXYesNo► Subscribe► Subscribe
King Pharms
LEVOXYL
levothyroxine sodium
TABLET;ORAL021301-007May 25, 2001AB1,AB3RXYesNo► Subscribe► Subscribe
King Pharms
LEVOXYL
levothyroxine sodium
TABLET;ORAL021301-008May 25, 2001AB1,AB3RXYesNo► Subscribe► Subscribe
King Pharms
LEVOXYL
levothyroxine sodium
TABLET;ORAL021301-009May 25, 2001AB1,AB3RXYesNo► Subscribe► Subscribe
King Pharms
LEVOXYL
levothyroxine sodium
TABLET;ORAL021301-010May 25, 2001AB1,AB3RXYesNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,555,581

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,067,148Stabilized pharmaceutical and thyroid hormone compositions and method of preparation► Subscribe
7,101,569Methods of administering levothyroxine pharmaceutical compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,555,581

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2438641► Subscribe
Canada2438907► Subscribe
Canada2440190► Subscribe
European Patent Office1365745► Subscribe
European Patent Office1474103► Subscribe
Japan2004525109► Subscribe
Japan2005517720► Subscribe
Norway20033636► Subscribe
Norway20033637► Subscribe
South Korea20040100835► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Chinese Patent Office
Colorcon
US Department of Justice
Cipla
McKesson
Teva
Cantor Fitzgerald
Citi
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot